Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke

Atherosclerosis

Volumn 201, Issue 1, 2008, Pages 130-137

  Kaplan, Robert C ^a   Smith, Nicholas L ^b,c,d   Zucker, Stanley ^e   Heckbert, Susan R ^b,d   Rice, Kenneth ^b   Psaty, Bruce M ^b,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d Center for Health Studies   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Genetics; Myocardial infarction; Stroke

Indexed keywords

GELATINASE B; STROMELYSIN;

ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INCIDENCE; INTRACRANIAL HEMORRHAGES; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; STROKE;

EID: 53849138794     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.01.003     Document Type: Article

References (28)

1. Zucker S., Hymowitz M., Conner C., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 878 (1999) 212-227
2. Galis Z.S., Sukhova G.K., Lark M.W., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
3. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 39 (2002) 279-291
4. Ye S., Eriksson P., Hamsten A., et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 271 (1996) 13055-13060
5. Beyzade S., Zhang S., Wong Y.K., et al. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 41 (2003) 2130-2137
6. Liu P.Y., Li Y.H., Chan S.H., et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol 98 (2006) 1012-1017
7. Zhou X., Huang J., Chen J., et al. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb Haemost 92 (2004) 867-873
8. Kim J.S., Park H.Y., Kwon J.H., et al. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J 43 (2002) 473-481
9. Lamblin N., Bauters C., Hermant X., et al. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 40 (2002) 43-48
10. Fornage M., Mosley T.H., Jack C.R., et al. Family-based association study of matrix metalloproteinase-3 and -9 haplotypes with susceptibility to ischemic white matter injury. Hum Genet 120 (2007) 671-680
11. Psaty B.M., Smith N.L., Heckbert S.R., et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 287 (2002) 1680-1689
12. Smith N.L., Hindorff L.A., Heckbert S.R., et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 297 (2007) 489-498
13. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and the risk of incident atrial fibrillation in women. Arch Int Med; in press.
14. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68 (2001) 978-989
15. French B., Lumley T., Monks S.A., et al. Simple estimates of haplotype relative risks in case-control data. Genet Epidemiol 30 (2006) 485-494
16. Flex A., Gaetani E., Papaleo P., et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 35 (2004) 2270-2275
17. Medley T.L., Kingwell B.A., Gatzka C.D., Pillay P., and Cole T.J. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 92 (2003) 1254-1261
18. Rosenberg G.A., Cunningham L.A., Wallace J., et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893 (2001) 104-112
19. Rosenberg G.A., Kornfeld M., Estrada E., et al. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 576 (1992) 203-207
20. Rosenberg G.A., Estrada E.Y., Dencoff J.E., and Stetler-Stevenson W.G. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 703 (1995) 151-155
21. Yamada Y. Identification of genetic factors and development of genetic risk diagnosis systems for cardiovascular diseases and stroke. Circ J 70 (2006) 1240-1248
22. Zhang B., Dhillon S., Geary I., et al. Polymorphisms in matrix metalloproteinase-1, -3, -9, and -12 genes in relation to subarachnoid hemorrhage. Stroke 32 (2001) 2198-2202
23. Yoon S., Tromp G., Vongpunsawad S., et al. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun 265 (1999) 563-568
24. Bini A., Itoh Y., Kudryk B.J., and Nagase H. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond. Biochemistry 35 (1996) 13056-13063
25. Lijnen H.R., Arza B., Van Hoef B., Collen D., and Declerck P.J. Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). J Biol Chem 275 (2000) 37645-37650
26. Ugwu F., Lemmens G., Collen D., and Lijnen H.R. Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3). Thromb Haemost 82 (1999) 1127-1131
27. Suzuki Y., Nagai N., Umemura K., Collen D., and Lijnen H.R. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 5 (2007) 1732-1739
28. Medley T.L., Cole T.J., Dart A.M., Gatzka C.D., and Kingwell B.A. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 24 (2004) 1479-1484